• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Factors Predicting Response to Treatment in Chronic HCV Genotype 3 Patients 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Factors Predicting Response to Treatment in Chronic HCV Genotype 3 Patients
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Factors Predicting Response to Treatment in Chronic HCV Genotype 3 Patients
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Factors Predicting Response to Treatment in Chronic HCV Genotype 3 Patients

    View/Open
    D Shoeb PhD.pdf (1.325Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    Studies to date have failed to identify the most effective treatment regimes for patients with chronic genotype 3 HCV infection. There is controversy regarding the role of cirrhosis in modifying response and disagreement regarding the impact of ethnicity on treatment outcome. Given the importance of genotype 3 HCV in the global epidemic and the lack of high quality research into this genotype, the purpose of this work has been to address some of the deficiencies in our understanding of the optimal management of this strain of hepatitis C. Specifically we have examined the following hypotheses:- 1) Patients from the Indian sub-continent (South Asians) will respond differently to therapy with pegylated interferon and ribavirin when compared to Caucasians. 2) An analysis of viral and host factors underlying differences between treatment sensitive and treatment refractory cohorts will reveal new insights into the virology of Genotype 3 HCV infection. 3) Increasing the duration of therapy in ‘difficult to manage’ patients with Genotype 3 HCV will improve response rates. 4) Whether non-invasive methods of identifying liver fibrosis are valuable in identifying the stages of fibrosis in Genotype 3 HCV patients. Three different research methodologies were used to address these questions including a metaanalysis of factors associated with treatment failure in patients with genotype 3 HCV, virological and immunological studies on patients with genotype 3 HCV who had failed to respond to therapy and a clinical trial evaluating extended duration therapy in patients with Genotype 3 HCV infection and cirrhosis.
    Authors
    Shoeb, Dania
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/8450
    Collections
    • Theses [3834]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.